Cellular Vehicles

Cellular Vehicles

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $25M

Overview

Cellular Vehicles is a private, pre-clinical stage biotech founded in 2018 and based in Cambridge, Massachusetts. The company is building an integrated technology platform focused on automating and scaling the formulation and delivery of cell therapies, aiming to solve critical bottlenecks in the manufacturing process. While still early-stage with a small core team, it is positioning itself at the intersection of advanced therapy manufacturing and targeted drug delivery. The company appears to be pre-revenue and is likely funded by venture capital or grants, though specific investors are not disclosed on its website.

Cell TherapyDrug Delivery

Technology Platform

Integrated platform combining microfluidics, robotics, and AI for automated formulation and dose preparation of cell-based therapies.

Funding History

2
Total raised:$25M
Series A$20M
Seed$5M

Opportunities

The company addresses the critical manufacturing bottleneck in the high-growth cell and gene therapy market.
Its platform enables scalable, consistent, and potentially decentralized production, which could significantly reduce costs and improve patient access to curative treatments.

Risk Factors

Key risks include technology execution and validation, competition from established life science tools companies and startups, and the challenge of convincing risk-averse biopharma clients to adopt a new, unproven manufacturing platform.

Competitive Landscape

Cellular Vehicles competes in the cell therapy manufacturing tools space against large incumbents like Thermo Fisher Scientific and Danaher (Cytiva), as well as numerous startups focused on automation, closed systems, and process analytics. Differentiation will hinge on the seamless integration of microfluidics, robotics, and AI for the specific formulation challenge.